Partnering & Outsourcing Editorial
-
Consultants, PPAs, And Loyalty: Trends In Phase II/III CRO Benchmarking
7/27/2021
ISR Reports recently released the 13th Edition of its Phase II/III CRO Benchmarking report. Many sponsor companies turn to CROs for the heavy lifting of their clinical development programs. Still, finding the service provider best suited to meet trial needs and performance expectations is a difficult task.
-
The 6 Pillars Of Effectively Managing Up In Clinical Development
7/22/2021
Managing up, regardless of title, can be a challenging skill to master from the onset. Laurie Halloran and Michelle Pratt of Halloran Consulting share their 6 key lessons that they've learned along their careers in clinical development. This article will help you manage your relationships with your colleagues in a more senior role, while also positioning yourself for success.
-
No CMOs Or CROs: A Unique Approach To Cell Therapy Development
7/22/2021
Cartesian Therapeutics has just 20 employees, but the company performs all its preclinical and regulatory work and clinical operations in-house. A few years ago, Cartesian also built a GMP manufacturing facility from the ground up. That gives the company its own quality management system and quality control labs. Learn how they do it.
-
The Right Precision Medicine Partner Is Essential For Trials And Patients
7/20/2021
Patient recruitment is a challenge for all pharma and biotech companies. Despite the advances made in patient centricity and decentralized trials, the recruitment remains challenging. Part of the reason might be that the advent of precision medicine is paradoxically not making the recruitment challenge any easier.
-
The Right Payment System Makes Bayer Healthcare A Sponsor of Choice
6/29/2021
Companies hoping to become a sponsor of choice have a lot to consider. They must think about how to improve interactions with patients, sites, CROs, and other service and equipment providers. When Bayer decided to go down the sponsor-of-choice path, there was one aspect of partnering they knew they had to get right: site payments.
-
How Lyndra Uses Trial Partners To Reinvent Medicine
6/11/2021
If you say that Lyndra Therapeutics is manufacturing a line of treatments around an extended-release capsule, don’t be surprised if someone from the company corrects you. Referring to their technology as an extended-release capsule is a gross understatement. Learn how Lyndra is applying its technology and partnering approach to reinvent medicine.
-
How To Educate Payers And Reduce Your Risk Of Failure
6/3/2021
With large drug developers leaving the space, the heavy lifting with antibiotics has been largely left to small biotech companies. Some of them have found success, only for them to be failed when it comes to commercialization of the product. RedHill Biopharma has a plan to educate payers and ensure success.
-
What You Must Know About APAC Before Deploying Your Next Clinical Trial
5/24/2021
Right now, no place in the world is a hotter spot to conduct clinical trials that the Asian-Pacific region (APAC). I spoke to industry consultant and Clinical Leader Editorial Board member, Michael W. Young, principal at biomedwoRx: Life Sciences Consulting, for his take on the growing clinical popularity of the region.
-
The Benefits Of A Functional Service Provider (FSP) Model In Uncertain Times
5/3/2021
Contract research outsourcing can be a challenging endeavor even in the best of times. Simply selecting the right model can be a difficult chore, and then there is the task of selecting the right partners, preparing contracts, and conducting oversight. When operating in uncertain times, the process becomes significantly more difficult.
-
From Medical Researcher To CEO
3/31/2021
Yan Chen used her industry experience and interest in immunology to start Elpis Biopharmaceuticals, a company hoping to find cures for difficult-to-treat cancers.